Advertisement

Topics

JSR Life Sciences to buy xell line developer Selexis

03:16 EDT 15 Jun 2017 | Pharmaceutical Business Review

JSR Life Sciences (JLS) has agreed to acquire life sciences firm and mammalian cell-line generation technologies provider Selexis for an undisclosed sum.

Original Article: JSR Life Sciences to buy xell line developer Selexis

NEXT ARTICLE

More From BioPortfolio on "JSR Life Sciences to buy xell line developer Selexis"

Quick Search
Advertisement